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It was already in the 18th century when the French surgeon LeDran first
noted that breast cancer patients with spread of tumor cells to their axil-
lary lymph nodes had a drastically worse prognosis than patients without
spread (LeDran et al., 1752). Since then, metastatic spread of cancer cells
to regional lymph nodes has been established as the most important prog-
nostic factor in many types of cancer (Carter et al., 1989; Elston and Ellis,
1991). However, despite its clinical importance, lymph metastasis remains
an underexplored area of tumor biology. Fundamental questions, such as
when, how, and perhaps most importantly, why tumor cells disseminate
through the lymphatic system, remain largely unanswered. Accordingly, no
treatment strategies exist that specifically target lymph metastasis. The
identification of epithelial-mesenchymal transition (EMT) as a mechanism,
which allows cancer cells to dedifferentiate and acquire enhanced migratory
and invasive properties, has been a game changer in cancer research. Con-
ceptually, EMT provides an explanation for why epithelial cancers with
poor differentiation status are generally more aggressive and prone to
metastasize than more differentiated cancers. Inflammatory cytokines, such
as TGF-b, which are produced and secreted by tumor-infiltrating immune
cells, are potent inducers of EMT. Thus, reactivation of EMT also links
cancer-related inflammation to invasive and metastatic disease. Recently,
we found that breast cancer cells undergoing TGF-b-induced EMT acquire
properties of immune cells allowing them to disseminate in a targeted fash-
ion through the lymphatic system similar to activated dendritic cells during
inflammation. Here, we review our current understanding of the mecha-
nisms by which cancer cells spread through the lymphatic system and the
links to inflammation and the immune system. We also emphasize how
imaging techniques have the potential to further expand our knowledge of
the mechanisms of lymph metastasis, and how lymph nodes serve as an
interface between cancer and the immune system.
Abbreviations
APCs, antigen-presenting immune cells; CTL, cytotoxic T lymphocytes; CXADR, coxsackie and adenovirus receptor; DC, dendritic cells;
EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; EndoMT, endothelial/mesenchymal transition; FDCs,
follicular dendritic cells; IVM, intravital two-photon microscopy; JAM-A, junction adhesion molecule A; LN, lymph node; MDSC, myeloid-
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associated macrophages; TGF-b, transforming growth factor beta; VEGF, vascular endothelial growth factor.
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1. Introduction
Metastasis is a complex process, during which cancer
cells—for not completely known reasons, migrate away
from the primary tumor, gain access to the circulation,
and subsequently home to distant organs—most fre-
quently the lungs and the liver, where they establish
growth. Recent data indicate that the metastatic pro-
cess is not entirely linked to tumor growth, per se, but
is controlled by other factors and can occur from early
lesions (Husemann et al., 2008). Although described as
a rather inefficient process, the formation of distant
metastases is what accounts for the largest numbers of
deaths from cancer (Fidler and Balch, 1987; Luzzi
et al., 1998). In contrast to locally growing tumors,
which generally have better prognosis as they can be
removed by surgical resection and/or by irradiation,
metastatic cancers are significantly less treatable.
Metastatic tumors tend to grow at multiple foci in dis-
tant organs and are difficult to remove surgically, or
by irradiation. In addition, metastatic cancer cells are
often resistant to treatment with chemotherapeutic
drugs. This may be explained by the fact that most
chemotherapeutic drugs have been developed to specif-
ically target the proliferative capacity of cancer cells
rather than their capacity to disseminate and grow at
distant sites, which are the characteristic properties of
metastatic cancer cells.
Metastatic spread of cancer cells requires dissemina-
tion via the systemic circulation. Circulating tumor
cells can be found in patients with almost any types of
cancer (Allard et al., 2004). However, the subject of
how they get access to the circulation is still a matter
of debate. Some tumor cells may intravasate into blood
vessels within the tumor microenvironment and thereby
get direct access to the circulation. Tumor blood vessels
induced by overexpression of vascular endothelial
growth factor (VEGF) often have discontinuous cell–
cell junctions and incomplete coverage of mural cells
(Baluk et al., 2005). As such, abnormal blood vessels in
tumors have incomplete vascular walls and are leaky
and may be used by tumor cells for intravasation. Yet,
although angiogenic inhibitors targeting the VEGF
pathway are quite efficient in blocking angiogenesis in
mouse tumor models, they have shown limited effects
on cancer progression and survival in human patients
(Vasudev and Reynolds, 2014). In fact, it was shown in
2009 that although angiogenic inhibitors targeting the
VEGF pathway block tumor growth in mouse models
of pancreatic neuroendocrine carcinoma and glioblas-
toma, they concomitantly elicit tumor adaptation and
progression toward higher malignancy grade (Paez-
Ribes et al., 2009), which was evident by increased
lymphatic and distant metastasis.
Spread of cancer cells to regional lymph nodes is the
most important prognostic factor in many types of
cancer including breast cancer, head and neck cancer,
prostate cancer, and colorectal cancer. In line with
this, lymphatic invasion may be the predominant
method of vascular invasion in breast cancer (Gujam
et al., 2014; Mohammed et al., 2007). In head and
neck cancers, the formation of distant metastasis was
for a long time believed to occur through hematoge-
nous dissemination (Calhoun et al., 1994; Leemans
et al., 1993; Leon et al., 2000). However, more recent
studies show that distant metastasis without lymph
node spread is unusual in oral cell squamous carcino-
mas, and patients staged N0, N1, N2, and N3 (N0: no
spread to lymph nodes; N1: spread to one lymph
node; N2: spread to more than one lymph nodes; N3:
spread to lymph nodes that are more than 6 cm in
size) have a 5-year survival rate of 63%, 32%, 26%,
and 11%, respectively (de Jong et al., 2001). Some
tumor cells have been shown to migrate into nondrain-
ing lymphatic vessels and form tumors, so-called skip
metastases. The incidence of skip metastases was in
1997 reported in 15.8% of 277 tongue cancer cases
(Byers et al., 1997).
Considering the construction of the lymphatic sys-
tem, it may not be surprising that this system repre-
sents a major route for dissemination of tumor cells.
In contrast to blood vessels, lymphatic vessels are built
for transport of fluid and cells—away from tissues.
Blind-ended lymphatic capillaries are formed by oak
leaf-shaped lymphatic endothelial cells overlapping
each other (Oliver and Detmar, 2002). When the inter-
stitial pressure increases in tissues, the space between
the endothelial cells widens, which creates the forma-
tion of gaps that allow influx of interstitial fluid (Gerli
et al., 2000). The creation of this one-way drainage
system, allowing fluid to flow in but not out, was pre-
viously interpreted as a defect of endothelial cells lack-
ing intercellular junctions. This theory fell short when
gene profiling data demonstrated the expression of
endothelial cell–cell adhesion molecules, such as plate-
let endothelial cell adhesion molecule 1 (PECAM-1),
junction adhesion molecule A (JAM-A), and occludin
(Kriehuber et al., 2001; Podgrabinska et al., 2002).
The final solution of how intercellular junctions are
organized in lymphatic capillaries came through high-
resolution imaging studies that demonstrated the exis-
tence of button-like junctions allowing gaps to form
and support intravasation of fluid and cells while
remaining intact (Baluk et al., 2007).
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Thus, one reason for why cancer cells may choose
lymphatic vessels over blood vessels for intravasation
is because lymphatic capillaries are structurally orga-
nized to support cellular trafficking away from tissues.
Yet, another important question is how cancer cells
find their way to lymphatic vessels—do they simply
migrate stochastically within the tumor microenviron-
ment until they randomly come in contact with a lym-
phatic vessel? Or, do mechanisms exist that actively
promote targeted migration of cancer cells toward
lymphatic vessels?
2. Immune cell trafficking through the
lymphatic system
Lymphatic vessels are not only serving as a transport
system for fluid and cells but represent an important
component of the immune system (Kataru et al., 2014).
The lymphatic system functions as an interface between
the innate and adaptive immunity, and actively com-
municates and senses inflammatory stimuli from the
periphery (Shields, 2011). The immune response, which
is mounted in draining lymph nodes, plays an impor-
tant role in coordinating the local response toward the
cause of the inflammatory response, and promotes tis-
sue-specific immunity. An essential part of the process
of mounting of an adaptive immune response in lymph
nodes is the activation and targeted migration of anti-
gen-presenting immune cells (APCs) from the periphery
and through the lymphatic system. Important cells in
this respect are dendritic cells (DC) that possess phago-
cytic and antigen presentation abilities (Randolph
et al., 2005). Although DCs are not the only migratory
cells, they are at the core of the activation of the adap-
tive immune system. At steady state, they are also
important in promoting peripheral tolerance and thus
have a dual role (Steinman and Nussenzweig, 2002).
Upon activation, DCs acquire migratory properties
characterized by distinct polarization of cellular actin
machineries (Vargas et al., 2016). The migratory capac-
ity of DCs is influenced by their subtype and by inflam-
matory cues (Worbs et al., 2017). Activated DCs in
peripheral tissues do not migrate randomly but rather,
in a targeted fashion toward lymphatic vessels, and fur-
ther toward draining lymph nodes. An important dri-
ver of the targeted migration of DCs through the
lymphatic system is the chemokine CCL21, which is
produced and secreted by lymphatic endothelial cells,
and its receptor CCR7, which is expressed at the sur-
face of activated DCs. Through their surface expression
of CCR7, activated DCs have the capacity to sense and
migrate toward lymphatic endothelial cells expressing
CCL21.
To generate an adaptive immune response that
includes antibody production, antigens also need to
reach the follicular dendritic cells (FDCs) that reside in
the B-cell follicles and are important for B-cell activa-
tion. In this respect, a number of mechanisms are
involved including active transport by phagocytes to
the lymph nodes (Heesters and Carroll, 2016). How-
ever, studies have also shown that small soluble
antigens can reach lymph nodes even without antigen-
presenting cells (Sixt et al., 2005). Such antigens are
processed and transported by subcapsular sinus macro-
phages (SSM) and B cells to FDCs. The SSM are tis-
sue-resident macrophages and are positioned so that
they can stretch between the lymphatic endothelial cells
to capture antigen. Alternatively, antigens may flow
into the conduit network, which makes up a tubular
system within lymph nodes allowing antigens below
70 kD to enter and be taken up by resident phagocytes
and FDCs (Gonzalez et al., 2011). After the B cell has
picked up its specific antigen from the FDC, it is pro-
cessed and presented to T cells activated by DCs. This
is a key event and the start of the germinal center reac-
tion, which leads to clonal selection and subsequently
specific antibody production. Activated effector lym-
phocytes can exit the lymph nodes and disseminate into
blood vessels (Weisel et al., 2016). These cells can sub-
sequently traffic to the inflamed site to perform cyto-
toxicity or, in the case of B cells, remain in secondary
lymphoid organs to produce antibodies, or migrate to
the bone marrow to become long-lived plasma cells
(Roth et al., 2014). Thus, immune cells interact with
lymphatic vessels in tissues and lymph nodes. They also
secrete factors that may induce remodeling of the lym-
phatic system through lymphangiogenesis, which is fre-
quently observed in chronic inflammatory and cancer
diseases (Kataru et al., 2014). Expansion of the lym-
phatic vasculature in tumors through lymphangiogene-
sis is linked to enhanced lymph metastasis (Ji, 2012;
Zumsteg and Christofori, 2012).
2.1. EMT in cancer metastasis
Epithelial-mesenchymal transition is a developmental
process whereby epithelial cells transdifferentiate into
mesenchymal cells, migrate to other regions of the
embryo, and form new cell types (Nieto et al., 2016).
Similar to other developmental processes, like angiogen-
esis and lymphangiogenesis, EMT is silent in normal,
healthy tissues. However, reactivation of EMT occurs in
pathological conditions including chronic inflammation,
fibrosis, wound healing, and cancer (comprehensively
reviewed in (Kalluri and Weinberg, 2009; Nieto et al.,
2016; Thiery et al., 2009). Epithelial cells undergoing
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EMT lose epithelial characteristics, such as components
of tight and adherens junctions, and apico-basal cell
polarity, and the cytoskeleton is reorganized to support
a more migratory state. Loss of E-cadherin expression,
one of the most frequently used markers for EMT, is
associated with a more invasive phenotype in many
types of human carcinomas (Frixen et al., 1991). The
regulation of E-cadherin has been widely studied, and
various transcription factors known for inducing EMT,
including Snail1/2, ZEB1/2, and Twist1/2 factors, func-
tion as direct or indirect repressors of E-cadherin
(Lamouille et al., 2014; Nieto and Cano, 2012). The
expression of these EMT factors is regulated by signal-
ing pathways involved in cellular stemness and transfor-
mation, including Ras, Notch, and WNT signaling, and
is often associated with poor prognosis and tumor
recurrence (Elloul et al., 2005; Fuxe et al., 2010; Martin
et al., 2005; Moody et al., 2005). Loss of tight junction
proteins including the coxsackie and adenovirus recep-
tor (CXADR) and occludin, are other hallmarks of
EMT, and contributes to loss of the epithelial barrier
(De Craene and Berx, 2013; Fuxe et al., 2010; Vincent
et al., 2009). Increased expression of mesenchymal pro-
teins, such as the intermediate filament protein vimen-
tin, contributes to the enhanced migratory properties of
EMT cells (Lamouille et al., 2014).
In addition to being more migratory, EMT cells dis-
play other properties associated with cancer progres-
sion and metastasis. As such, EMT cells can avoid
senescence. Twist factors can disarm oncogene-induced
senescence by inhibiting the tumor suppressor proteins
p16 and p21, alongside inducing EMT (Ansieau et al.,
2008). Furthermore, early studies provided evidence for
the role of EMT in drug resistance (Sommers et al.,
1992). High levels of vimentin were detected in adri-
amycin-resistant cell lines, where some cells in a hetero-
genic population possessed typical EMT features. This
suggested that EMT cells have advantages in growth
capabilities compared to non-EMT cells after drug
treatment. Drug resistance is often accompanied with
EMT and has been reported in several cancer types like
breast and pancreatic cancer (Singh and Settleman,
2010). High levels of E-cadherin are associated with
sensitivity to epidermal growth factor receptor (EGFR)
kinase inhibitors, whereas the opposite is true for cells
with low levels of E-cadherin and a mesenchymal phe-
notype. Cells expressing EMT markers have also been
shown to have a higher resistance to drugs such as
oxaliplatin and paclitaxel (Kajiyama et al., 2007; Yang
et al., 2006). Recent studies using animal models
emphasize the role of EMT as an important mechanism
of chemoresistance (Fischer et al., 2015; Shibue and
Weinberg, 2017; Zheng et al., 2015).
2.2. Inflammation as an EMT inducer
Recently, much attention has been drawn to the
inflammatory milieu within tumors, and infiltrating
immune cells have been found to play both anti- and
protumorigenic roles. Subtypes of tumor-associated
macrophages (TAMs), regulatory T cells, and myeloid-
derived suppressor cells (MDSC) have been identified
as promoters of tumor progression and metastasis.
These cells produce and secrete cytokines such as
transforming growth factor beta (TGF-b), which may
induce EMT, and contribute to an immunosuppressive
tumor microenvironment by switching the polarization
of immune cells (Fuxe and Karlsson, 2012).
Transforming growth factor beta-b is frequently over-
expressed in cancer and inflammatory tissues (Lamouille
et al., 2014; Massague, 2008; Moustakas and Heldin,
2016). The TGF-b paradox refers to its function both as
a tumor suppressor and as a promoter. Normally, TGF-
b controls tissue homeostasis by coordinating apoptosis,
and inhibits incipient tumor growth (Massague, 2008).
However, during tumor progression, TGF-b switches
from a tumor suppressor to a promoter of EMT and
resistance to cell death. Breast cancer cells treated with
TGF-b for several weeks stay in EMT and avoid apop-
tosis (Gal et al., 2008). TGF-b signals through a canoni-
cal Smad signaling pathway, which involves
phosphorylation and activation of receptor-Smads 2/3,
which then interact with Smad4. The Smad complex
enters the cell nucleus, where it regulates the transcrip-
tion of TGF-b target genes. However, Smads have low
affinity for DNA binding and need to interact with
cofactors to achieve target gene specificity (Massague,
2008). The identification of Snail1, a master regulator of
EMT, as a cofactor for Smad3/4 opened up a new
understanding of how TGF-b cooperates with onco-
genic pathways like Ras-MAPK, Notch, and WNT/b-
catenin to induce EMT (Fuxe et al., 2010; Vincent
et al., 2009). Interestingly, TGF-b can also promote
endothelial/mesenchymal transition (EndoMT), which
also requires Snail1 and Smad transcription factors
(Kokudo et al., 2008; Mihira et al., 2012). EndoMT
may contribute to the generation of fibroblasts/myofi-
broblasts in fibrotic diseases (Piera-Velazquez et al.,
2016), but its role in cancer metastasis is not clear.
2.3. EMT cells hijack the immune system to
disseminate through the lymphatic system
It has not been clear what drives cancer cells to dis-
seminate through the lymphatic system, and whether
EMT contributes to this process. However, recent data
have shed some new light on this question. Our
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experiments demonstrated that cancer cells that
undergo TGF-b-induced EMT acquire an enhanced
capacity to disseminate through the lymphatic system
(Pang et al., 2016). Using a novel three-dimensional
coculture system, in which EMT cells grown on poly-
meric beads were analyzed for their capacity to
migrate toward beads coated with either blood or lym-
phatic endothelial cells, we found that EMT cells pref-
erentially migrate toward lymphatic compared to
blood endothelial cells. These data indicated that lym-
phatic endothelial cells may produce chemotactic fac-
tors that attract EMT cells. Considering the well-
known role of the chemokine receptor CCR7 and its
ligand CCL21 in promoting dissemination of DCs
through the lymphatic system, we studied whether
CCR7/CCL21-mediated chemotaxis could play a role
in targeting EMT cells to lymph nodes. The CCR7
receptor is functioning as an activator of DCs and
lymphocytes, and plays an important role for targeted
DC migration through the lymphatic system to lymph
nodes (Platt and Randolph, 2013). CCR7 has also
been shown to mediate lymphatic dissemination of
cancer cells (Cunningham et al., 2010; Shields et al.,
2007).
In our studies, we found that CCR7 was induced in
cancer cells undergoing TGF-b-induced EMT (Pang
et al., 2016). Further studies revealed that CCR7 medi-
ated lymph node metastasis of EMT cells. The ligand
CCL21 is expressed on lymphatic endothelial cells and
serves as an important chemoattractant for migrating
DCs. We found that CCL21 produced by lymphatic
endothelial cells was important for the capacity of
EMT cells to migrate toward lymphatic endothelial
cells. Moreover, the data showed that TGF-b induced
the expression of CCL21 in lymphatic, but not in
blood endothelial cells. Thus, TGF-b-induced EMT in
cancer cells appears to activate a mechanism used by
the immune system to direct migration of DCs
through the lymphatic system (Fig. 1). In line with
this, others have found that lymphatic endothelial cells
may express other chemokines used by tumor cells for
lymph node metastasis (Table 1). The CXCR5 recep-
tor and its ligand CXCL13 have been linked to EMT
and lymph metastasis in breast cancer (Biswas et al.,
2014). The chemokine CXCL12 was found to be
upregulated in the lymphatic endothelium of draining
lymph nodes, alongside migrating tumor cells express-
ing the CXCR4 receptor (Hirakawa et al., 2009), and
this system is linked to TGF-b-induced EMT (Bertran
et al., 2009; Taki et al., 2008). Another chemokine,
CCL1, was shown to promote lymph node entry of
melanoma cells expressing the receptor CCR8, whereas
blocking of CCR8 function resulted in decreased
lymph node metastasis (Das et al., 2013). Inhibition of
CCR8 additionally prevented tumor cells from lymph
node entry, creating an arrest of tumor cells in the
afferent lymphatic vessels. Together, these results indi-
cate that TGF-b-induced EMT provides cancer cells
with the capacity to hijack various chemotactic signals
and use them for dissemination through the lymphatic
system similar to activated DCs during inflammation.
Considering the possibility that cancer cells undergo-
ing EMT may acquire additional properties of immune
cells, we performed gene profiling analysis of breast
cancer cells that had been allowed to adopt an EMT
program after treatment with TGF-b for 2 weeks.
Intriguingly, a cluster of genes, which are normally
expressed in myeloid type of immune cells including
macrophages and DCs, were induced in the EMT cells
(Johansson et al., 2015). These genes encode proteins
with variable intracellular localization and molecular
function, and while some of them previously have been
linked to cancer metastasis, others have not. Our con-
clusion from these studies is that cancer cells undergo-
ing TGF-b-induced EMT adopt features of immune
cells and that the term ‘mesenchymal’ actually is insuf-
ficient to describe the properties of EMT cells. It will
be interesting for future studies to further examine to
what extent EMT cells make use of immune cell prop-
erties to disseminate to lymph nodes and further to
distant sites. Intriguingly, the only cells in human bod-
ies that actually share the capacity with prometastatic
cancer cells to disseminate through the vascular sys-
tems and home to distant organs are immune cells.
3. New technical advances to study
metastasis
Sites of regional lymph node spread have been termed
‘bridgeheads’, suggesting that they serve as bridges
assisting further spread (Sleeman, 2000). However, the
mechanisms by which cancer cells migrate both within
lymph nodes and further to other sites remain poorly
studied. We foresee that the rapidly evolving field of
tumor imaging will lead to better insight into this.
Macroscopic imaging techniques such as MRI, CT,
and PET are mostly applied to clinical practice and
allow the visualization of tumors as well as the evalua-
tion of cancer therapy. Microscopic techniques,
instead, allow the characterization of molecular mech-
anisms that underlie metastasis, and cell–cell interac-
tions in vivo, which are needed to study the dynamic
behavior of metastatic cells (Condeelis and Weissleder,
2010).
Advances in photonics have enabled the develop-
ment of intravital two-photon microscopy (IVM), a
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revolutionary technique that allows the study of cell
migration in living organisms at cellular and subcellu-
lar resolution (Stein and Gonzalez, 2017). The advan-
tage of this technique, compared to classical imaging
methods, resides in the use of low-energy infrared pho-
tons that allow the visualization of cells at a greater
specimen depth (typically from 100 to 1000 lm), while
minimizing tissue photodamage and photobleaching
caused by exposure to laser radiation during the image
acquisition process (Warren et al., 2003). Moreover,
IVM has benefited from the generation of constitutive
or inducible fluorescent reporter mouse strains, which
have been used for the study of different processes
such as the visualization of immune cell interactions
(Niesner and Hauser, 2011), the study of the structure
and morphology of the lymphatic system (Choi et al.,
2011), and the oncogenic transformation and tumor
regression in vivo (Ventura et al., 2007). The applica-
tion of this powerful technology to cancer studies has
provided new insights into the spatiotemporal dynam-
ics of tumor progression and the understanding of
how the interaction between tumor cells and the stro-
mal compartment influences this process.
However, in order to apply IVM, it is necessary to
develop proper microsurgical animal models that com-
bine a minimally invasive surgery, while keeping the
organ completely immobilized, which is required for
Fig. 1. Cancer cells undergoing TGF-b-induced EMT acquire properties of immune cells allowing them to disseminate through the lymphatic
system similar to DCs during inflammation. Upon activation, DCs acquire cell surface expression of the chemokine receptor CCR7, which
allows them to sense and migrate in a targeted fashion toward lymphatic capillaries secreting the CCR7 ligand, CCL21. Endothelial cells of
lymphatic capillaries are oak leaf-shaped and are connected through button-like junctions, which allows cells to intravasate without junctional
disorganization. Subsequently, DCs migrate to lymph nodes where they interact with other cells of the immune system and perform antigen
presentation. Recent studies show that similar to activated DCs, cancer cells undergoing TGF-b-induced EMT gain the expression of CCR7
and migrate in a targeted fashion through the lymphatic system (Pang et al., 2016). TGF-b may also enhance the migration of EMT cells
toward lymphatic capillaries by inducing the expression of CCL21 in lymphatic endothelial cells. It remains to be determined how EMT cells
migrate and interact with the immune system within draining lymph nodes.
Table 1. Chemokine receptors and ligands linked to TGF-b-induced
EMT and lymphatic dissemination of cancer cells.
Receptors Ligands References
CCR7 CCL21 Pang et al. (2016)
CCR8 CCL1 Das et al. (2013)
CXCR4 CXCL12 Hirakawa et al. (2009),
Bertran et al. (2009),
Taki et al. (2008)
CXCR5 CXCL13 Biswas et al. (2014)
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the stable acquisition of micrographs. One of the most
commonly used models in IVM is the mouse popliteal
lymph node (LN) (Fig. 2) developed by Mempel and
colleagues more than a decade ago (Mempel et al.,
2004). The selection of this organ as the model to
study cell migration is associated with its prominent
lymphatic drainage that originates from the mouse
footpad (Fig. 2A), and facilitates the direct observa-
tion of migratory cells from the injection site to the
LN (Fig. 2B; (1) and (2), respectively) (Stein and Gon-
zalez, 2017). Additionally, the development of trans-
genic fluorescent reporter mouse strains, such as the
Prox1-GFP (Choi et al., 2011), in which lymphatic
endothelial cells are labeled through expression of
GFP, has been a valuable tool to study cell migration
through the lymphatic system (Fig. 2A).
Despite being one of the key indicators of tumor
aggressiveness, the mechanisms of lymphatic dissemi-
nation of tumor cells remain elusive. To date, only rel-
atively few studies have focused on the migration of
cancerous cells through the lymphatic system using
IVM models. Recently, Das et al. (2013) monitored,
using IVM, the metastasis of melanoma cells in the
draining LN. The authors observed that the egress of
the tumor cells from the afferent lymphatics to the
subcapsular sinus area of the LN is an active mecha-
nism directed by the chemokine CCL1. Secretion of
the latter by lymphatic endothelial cells at the junction
between the afferent lymphatics and the subcapsular
sinus allows the entry of CCR8-expressing tumor cells
into the node and their subsequent metastasis.
Other studies have concentrated in the in vivo exam-
ination of the encounter of the migratory tumor cell
by the immune system. The LN is a highly compart-
mentalized organ with specific cell groups populating
its different areas (Fig. 2C). Among them, subcapsular
sinus macrophages (SCS), located next to the afferent
lymphatics, act as ‘flypaper’, preventing the dissemina-
tion of antigen and pathogens (review in Stein and
Gonzalez, 2017). Moalli and colleagues have recently
characterized a mechanism by which tumor-derived
antigen (TDA) induces humoral immune responses in
tumor-bearing hosts (Moalli et al., 2015). Using IVM,
the authors reported that the capture of TDA was
associated with SSM and B cells, and they were both
involved in the transport of TDA to the follicular den-
dritic cell network, located inside the follicle. On the
other hand, Junankar et al. (2015) found that the anti-
tumoral action of bisphosphonates, a drug commonly
used for the treatment of osteoporosis, was related to
the elimination of tumor-associated macrophages that
facilitate tumor progression (Junankar et al., 2015).
Furthermore, other studies focusing on the interac-
tions of effector immune cells with tumor cells in the
LN have also been performed using IVM. Deguine
and colleagues found that natural killer cells estab-
lished mainly dynamic contacts with their target cells
during tumor regression, while, conversely, cytotoxic T
lymphocytes (CTL) formed stable contacts with tumor
cells that expressed their cognate antigen (Deguine
et al., 2010). Similarly, Boisonnas and colleagues
imaged the arresting and killing of tumor cells by
adoptively transferring CTL that recognized the
expression of cognate antigen. Interestingly, the
authors found that CTL infiltrate tumors in depth
only when the tumor cells express the cognate CTL
A B C
Fig. 2. Intravital imaging techniques to study lymphatic dissemination of cancer cells. (A) Photomerge composition of lymphatic and blood
circulatory systems of the lower hind limb of a Prox1-GFP mouse. In the upper box, white arrows indicate a lymphatic valve and the
saphena artery. In the main figure, white arrows indicate the afferent vessels, the saphena artery, and the popliteal lymph node (LN). (B)
Schematic representation of the surgical intravital two-photon model in which two different areas of the limb are imaged. On the one hand,
the injection site, located in the footpad (1), and on the other hand, the popliteal area, where the arrival of the cancer cells is monitored (2).
After administration of anesthesia, the animal is immobilized, the popliteal LN is surgically exposed, and interactions between the cancer
and immune cells are recorded using intravital two-photon microscopy. (C) Schematic representation of the most representative areas and
immune cell populations in the popliteal LN. SSM, subcapsular sinus macrophages; MM, medullary macrophages; DC, dendritic cells; B, B-
cell follicle.
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antigen. Conversely, the infiltration of CTL was
restricted to peripheral regions in tumors that do not
express the cognate antigen (Boissonnas et al., 2007).
These studies have demonstrated the power of IVM
as a unique technique to elucidate in vivo the mecha-
nisms behind tumor progression. This could also be
applied to study the effects on tumors when using
checkpoint inhibitors (Sharma and Allison, 2015). Cur-
rently, this treatment that targets T cells is changing
the way cancer is treated, and there is a drive to
enhance the effect of this type of therapy to benefit
more patients (Khalil et al., 2016). IVM will be impor-
tant to evaluate how immunotherapy affects infiltra-
tion of CTLs and other immune cells in the TME.
Besides activation of T-cell responses, modulation of
other immune cells within the stromal compartment
including tumor-associated macrophages (TAM) is an
attractive option (Ngambenjawong et al., 2017). Also
here, IVM could be used to investigate the dynamics
of CTL responses when altering the microenvironment.
Future IVM studies will provide further insights into
the dynamics of lymphatic dissemination and metasta-
sis in different models of cancer, opening the door to
the development of novel strategies intended to control
the progression of the disease.
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